ArticleThe Pan African medical journal2024
Correlates of retinopathy in persons living with type 2 diabetes at a clinic in Zambia.
Article in The Pan African medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: diabetes mellitus presents a significant public health challenge globally, with its prevalence projected to rise, particularly in developing countries. Diabetic retinopathy is a common complication of diabetes and a leading cause of blindness among adults. Despite its significance, research on diabetic retinopathy in sub-Saharan Africa, including Zambia, remains limited. This study aimed to determine the prevalence of diabetic retinopathy and identify associated factors among individuals with type 2 diabetes mellitus (T2DM) attending Mahatma Gandhi Clinic in the Livingstone District of the Southern Province of Zambia. Methods: this was a cross-sectional study, involving 48 participants aged 18 years and above, living with T2DM, and enrolled at Mahatma Gandhi Clinic in Livingstone District of Southern Province, Zambia. The primary outcome was diabetic retinopathy, which was classified using the international classification of diabetic retinopathy. Both univariate and bivariate analysis were used to estimate the prevalence of diabetic retinopathy, whereas, logistic regression was used to determine the bio-demographic, social, and clinical variables associated with diabetic retinopathy. Results: the majority were females (n=37, 77.1%). The median age was 54 years (interquartile range (IQR) 48, 65). The mean Body Mass Index (BMI) was 27.4 (standard deviation (SD), ±6.0). The median duration of living with T2DM was 60 months (IQR, 36,132), with a mean pulse pressure of 9.6 ± 2.8 mmHg and mean glycosylated hemoglobin (HBA1C) of 9.58 ± 2.77%. Fifty percent of the participants had visual problems and hypertension (n=24 each, 50%,). Most participants reported not exercising for at least 30 minutes (n=37, 77.1 %,) and had uncontrolled sugar levels (n=32, 66.7%). Of the 48 participants, 12 (25%) had diabetic retinopathy. Longer duration of T2DM was the only factor significantly associated with diabetic retinopathy on multivariable analysis (AOR: 1.01; 95%Cl 1.00, 1.03, p<0.038). Conclusion: this study highlights a high prevalence (25%) of diabetic retinopathy among people living with type 2 diabetes mellitus (T2DM) being managed at Mahatma Gandhi Clinic in the Livingstone District of the Southern Province of Zambia. Longer duration of living with T2DM was positively associated with diabetic retinopathy. There is a need to provide routine eye examinations in this population and increase knowledge among clients living with T2DM to reduce the burden of diabetic retinopathy in our setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.